Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update

Core Viewpoint - Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is experiencing a stabilization in its share price following a significant pipeline update, despite a year-long decline of nearly 64% in its stock value [2]. Group 1: Pipeline Update - On December 18, 2025, Sangamo announced the initiation of a rolling Biologics License Application (BLA) submission to the U.S. FDA for isaralgagene civaparvovec (ST-920) aimed at adults with Fabry disease, which could expedite the regulatory process [3]. - The registration STAAR study data supports the BLA, showing ST-920's potential as a one-time, durable gene therapy, with the FDA validating that the mean annualized eGFR slope at 52 weeks can serve as an accelerated approval endpoint [4]. Group 2: Company Overview - Sangamo Therapeutics is a clinical-stage biotech company focused on developing genomic medicines for inherited metabolic, neurologic, and immune diseases, utilizing gene therapy and genome engineering platforms for potentially curative treatments [5].